Clinical studies on various immunological parameters in patients with pulmonary cancer i. correlations with clinical stages
Medical Journal of Hiroshima University 34(3): 331-354
The immunological activities of 144 patients with primary cancer were investigated using various immunological parameters and the following results were obtained: (1) Lymphocyte responsiveness to PHA and PWM of the patients with pulmonary cancer was significantly lower than that of healthy subjects and of the patients with pulmonary tuberculosis. (2) The fall of the lymphocytic function itself was found to largely contribute to reduction of lymphocyte responsiveness and it was also found that the inhibitory factor in plasma modified the lymphocytic reactivity change. (3) The lymphocyte responsiveness to PHA and PWM observed in the patients with pulmonary cancer reflects the immunological status of such patients, and was thought to serve as an index for prognosis. (4) As regards the correlation between the factor which determined the stage of pulmonary cancer and the absolute number of the lymphocyte, the grade of lymphnode metastasis exerted the largest effect on lymphocyte responsiveness, and the decrease of the absolute number of the lymphocyte appeared to take place in the progressive stage. (5) There were no consistent changes in the percentages of the T-cell and B-cell in relation to the stage determining factors, suggesting a little correlation between them. (6) Reactivities to the PPD skin test and the PHA skin test were both decreased with the progress of the stage, and the decreases showed good correlations to the prognostic condition of patients, indicating their usefulness as immunological parameter. (7) The values of .alpha.-globulin and .beta.-globulin, isolated by serum protein fractionation, showed increase with the progress of the stage, indicating also their usefulness as immunological parameter. (8) The level of immunoglobulin in pulmonary cancer patients showed no consistent correlations with the stages of the cancer. (9) The CEA level in peripheral blood of patients with various cancers was markedly higher than that in patients with benign diseases, and the value higher than 5 ng/ml was highly suspected of malignant tumor. (10) The level of blood CEA was found to be variable depending upon the type of the pulmonary cancer. Thus, the case with adenoma showed the highest reactivity, followed by that with flat epithelial cancer, and only a few positive cases were noted for undifferentiated cancer group. (11) In the case of pulmonary cancer, the level of the blood CEA increased with the progress of the stage, as was well correlated with clinical stages.